About You

Axiron® is supplied as a solution in a metered-dose pump that provides 30 mg of testosterone per actuation. Only six of 205 subjects in the gel groups discontinued therapy; two were related to drug specific adverse effects (hypertension and mood swings). Overall, there was a significantly lower number of skin irritation events in the gel groups compared to the patch group. Study subjects received either 50 or 100 mg of Vogelxo® daily, while the patch delivered 5 mg of testosterone daily.
Men who were taking medication known to affect androgen production and/or testosterone were likewise excluded. Increasing patient age and increasing duration of prior exogenous testosterone use both significantly reduced the likelihood of reaching the 5 million TMSC benchmark. Older meta-analyses from 2007 and 2005 similarly demonstrated no impact of testosterone on lipid profiles.312, 327
It is recommended to check a testosterone level between 4 to 12 weeks after therapy initiation prior to the morning dose (14). The preparation mimics physiological circadian testosterone rhythm, with serum levels quickly increasing after insertion and peak levels obtained by the second dose with no accumulation over time (15). Mimicking this natural pattern with a twice-weekly injection protocol helps maintain more stable testosterone levels. To date, limited data suggest that SC administration of testosterone enanthate and cypionate results in stable and predictable on-treatment concentrations, has good acceptability among patients, and can be self-administered more easily than IM injections. Among transgender men, patients who had previously used IM testosterone therapy with long-acting esters did not want to revert back to IM injections after they were started on SC testosterone therapy (24, 28, 51). Indeed, long-term compliance among men who are prescribed testosterone therapy with IM injections is low; approximately 69% of men on long-acting esters discontinue treatment within 3 months of therapy, and 95% discontinue it within 12 months (56). In a large study that used an SC autoinjector to administer weekly doses of testosterone enanthate ( mg/week) for 26 weeks, 87 of 133 participants experienced a treatment-emergent adverse event (an adverse event that started or worsened after the first dose) during the study (29).
One trial with three years of follow-up showed near linear, time-dependent improvements in BMD.202 These findings are similar to other prospective, controlled data, which report an estimated 5% per year increase in BMD in men on testosterone therapy.309 Declining bone density may necessitate additional medical intervention, such as weight bearing exercise, calcium, vitamin D, or bisphosphonate medications. As with other symptoms, the duration of testosterone therapy likely has a significant impact on overall bone density benefits. Given the link between LTBF and morbidity and mortality in older men, evaluating bone density is an important step in the assessment of patients with testosterone deficiency. At the present time, there are insufficient data available to predict which men with ED are most likely to respond to testosterone therapy. A 2005 meta-analysis by Calof et al.190 pooled data from 19 RCTs to determine the number of all-cause prostate events in men who were on exogenous testosterone treatment compared to men who were on placebo. The Testim Registry in the United States followed PSA changes in men without prostate cancer who were on testosterone therapy.
Several blood samples were collected over a 48-hour period to evaluate serum testosterone levels. The dose can be adjusted in increments of 10 mg, based on serum levels measured two hours after morning application 14 and 35 days after initiation or adjustments. On day one, serum testosterone was within physiological range in both gel groups, reaching a Cmax of 560±31 ng/dL in the 50 mg/day group after 22 hours of application and 745±40 ng/dL in the 100 mg/day group after 16 hours. Two weeks after initiation of therapy, a serum testosterone level should be measured (early morning after patch application the night prior) and patch dosing adjusted as necessary.
Mean Cavg and Cmax for all dosing regimens were within normal range on day 120. At this time, 10 patients were receiving 120 mg, 25 were titrated to 90 mg, 97 were still receiving 60 mg, and 3 patients had decreased to 30 mg/day. The dose can be adjusted in 30 mg increments up to a maximum of 120 mg or a minimum of 30 mg/day (37).
Consistent with a previous study of SC TE,32 SC weekly dosing achieves stabilized physiologic T levels over a one‐week dosing interval after injection, and minimizes large peak and trough differences as seen with some other TTh.31 Following 12 weeks on SC TE treatment, the 7‐day mean total T concentration (Cavg0‐168h) was 19.2 ± 4.4 nmol/L (553.3 ± 127.3 ng/dl). The primary endpoint was met, with 92.7% of overall patients achieving T levels within physiologic range of 10.4 to 38.1 nmol/L (300–1100 ng/dl).

Profile Info